Category Archives: General

No Comments on SARS-CoV-2 and Mitochondrial Health

A Current Publication by Dr. Wolfgang Brysch On the Prevention and Treatment of Covid-19 

Dr. Wolfgang Brysch
MetrioPharm CEO Dr. Wolfgang Brysch

Which are the factors that determine the course of a Covid-19 infection? Whether patients develop symptoms, whether they fall seriously ill, whether they need to be treated in a hospital? 

A decisive factor seems to be the age of the patient...

Read more

No Comments on “Breaking the vicious COVID cycle at an early stage”

Six questions and answers by MetrioPharm CEO Dr. Wolfgang Brysch on the compound MP1032 in COVID-19

Dr. Wolfgang Brysch
MetrioPharm CEO Dr. Wolfgang Brysch

Is MetrioPharm developing a compound for the treatment of COVID-19?

Wolfgang Brysch: We are developing our lead compound MP1032 for the treatment of chronic inflammatory diseases, with the molecule targeting oxidative stress. Oxidative stress also plays a central role in COVID-19 disease...

Read more

No Comments on „A Promising Start“

Background Discussion on MetrioPharm’s Preclinical COPD Study

Dr. Sara Schumann, Project Manager Research & Development at MetrioPharm, has led the preclinical study

MetrioPharm recently completed a study in a new preclinical model. What did this model look like?

Dr. Sara Schumann: For this initial study we chose an ex vivo model, in which the tests are performed on an isolated heart and lung system...

Read more

No Comments on MetrioPharm in the FAZ

Article from the Frankfurter Allgemeine Zeitung from December 24, 19:

© All rights reserved. Frankfurter Allgemeine Zeitung GmbH, Frankfurt.
To the newspaper article in the archive of the Frankfurter Allgemeine
Read more

No Comments on Ask the CEO – 6

Who Wants To Live Forever?

Dr. Wolfgang Brysch
CEO Dr. Wolfgang Brysch

2019 was the year of spectacular news, generated from the field of aging research. Supposedly, scientists had succeeded in slowing down the aging process, stopping it, even reversing it. As if life was an hourglass and we had learned how to stop time from running out by popping a pill, or even how to reverse the life flow.

Read more

No Comments on “A Most Extraordinary Result”

A Conversation About MetrioPharm AG’s Phase II Clinical Trial

 l.t.r.: Wolfgang Brysch, Chief Executive Officer
Barry Frankel, Senior Vice President Strategy and Business Development

MetrioPharm AG has just published Top Line Data for the Phase II clinical trial in psoriasis. Was the study a success?

Wolfgang Brysch: Yes, the study was clearly a success. We had a number of specific questions and were able to answer most of them...

Read more

No Comments on Focus on InflammAging

The connection between chronic inflammation and diseases of aging

Is there a problem with increasing life expectancy? If you look at the graph of average life years alone, the development over the last fifty years looks very positive. This graph shows a steady upward trend, especially in Western countries. People are getting older continuously.

There is, however, a second graph that has risen much slower: that of healthy life expectancy...

Read more

No Comments on »MetrioPharm Is at a Pivot Point«

A Conversation with Barry Frankel, MetrioPharm’s new Senior Vice President Strategy and Business Development

Barry Frankel, MetrioPharm’s Senior Vice President Strategy and Business Development.

Do you remember first hearing about MetrioPharm?

Yes, I do remember. I have a friend, who told me to take a look at this company. I reviewed their data and the first thing I liked was the unique profile of the MP1032 platform...

Read more

No Comments on Preparations for New Studies

A report on the current projects of the MetrioPharm team

Photo: © Sandra Meissner

Timetables on the office walls, e-mails with long to-do lists and meetings of all project groups: The new year has started off busy. In order to move the MetrioPharm pipeline ahead as planned, the team is coordinating several major projects simultaneously.

One of the most important is the completion of the Phase II trial in the indication psoriasis...

Read more